RxDoctor Payments Data

Stephen Donahue, MD

Neurology · Savannah, GANPI 1164746624

Payments from drug & device makers

$24,986in general payments, 2019–2025

Across 1,645 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • EMD Serono, Inc.$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • Biogen$1K
  • Mallinckrodt Hospital Products Inc.$946
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$790%
  • Food & beverage$24,892100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)221$3,193
EMD Serono, Inc.262$2,493
UCB, Inc.82$1,439
Novartis92$1,396
Biogen78$1,319
Mallinckrodt Hospital Products Inc.49$946
Pfizer39$783
Lundbeck LLC36$760
AstraZeneca(2 entities)35$731
Teva Pharmaceuticals USA, Inc.65$720
Sunovion Pharmaceuticals Inc.46$648
Amgen(2 entities)40$633
SK Life Science, Inc.27$621
Neurelis, Inc.33$612
Genentech USA, Inc.30$580
Eisai Inc.29$511
Jazz Pharmaceuticals Inc.33$483
TG Therapeutics, Inc.14$421
Ipsen Biopharmaceuticals, Inc22$408
CSL Behring17$355
Bristol Myers Squibb20$299
Argenx US, Inc.14$295
Neurocrine Biosciences, Inc.13$276
Greenwich Biosciences, Inc.11$268
Tanabe Pharma America, Inc.17$257
Lilly USA, LLC10$231
Avanir Pharmaceuticals, Inc.14$207
Averitas Pharma Inc.9$194
Supernus Pharmaceuticals, Inc.91$193
Takeda Pharmaceuticals U.S.A., Inc.9$189
Sumitomo Pharma America, Inc.10$187
Harmony Biosciences LLC11$187
Biohaven Pharmaceutical Holding Company Ltd.9$183
Acadia Pharmaceuticals Inc11$182
Octapharma USA, Inc.8$174
Mallinckrodt Enterprises LLC9$161
Catalyst Pharmaceuticals, Inc.8$144
Vanda Pharmaceuticals Inc.7$143
Merz Pharmaceuticals, LLC8$141
Acorda Therapeutics, Inc10$136
Kyowa Kirin, Inc.6$119
Otsuka America Pharmaceutical, Inc.6$113
Biohaven Pharmaceuticals, Inc.6$112
E.r. Squibb & Sons, L.L.C.3$111
Johnson & Johnson(2 entities)5$108
Sanofi5$92
Grifols USA, LLC4$92
Scilex Pharmaceuticals Inc.4$79
Merz North America, Inc.4$79
Livanova USA, Inc.3$69
Aquestive Therapeutics, Inc.4$69
Banner Life Sciences, LLC3$61
Alnylam Pharmaceuticals Inc.3$59
Immedica Pharma US, Inc.3$57
Boston Scientific4$57
Upsher-smith Laboratories LLC3$55
Bausch Health US, LLC3$52
ANI Pharmaceuticals, Inc.2$50
Hospira, Inc.2$46
Axsome Therapeutics, Inc.2$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,986 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$1,946,391
Medicare patients
1,027
Services billed
126,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4637$451,821
VumerityDiroximel Fumarate42$358,747
Nurtec OdtRimegepant Sulfate127$152,649
UbrelvyUbrogepant118$142,635
Aimovig AutoinjectorErenumab-Aooe120$110,931
NuplazidPimavanserin Tartrate18$100,540
XcopriCenobamate74$98,774
QuliptaAtogepant77$91,408
Teriflunomide17$70,092
QutenzaCapsaicin/Skin Cleanser15$53,802
KeppraLevetiracetam20$47,617
RexultiBrexpiprazole22$39,232
Ajovy AutoinjectorFremanezumab-Vfrm40$35,654
LamictalLamotrigine18$30,204
AptiomEslicarbazepine Acetate17$26,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$92$451,82137 claims
BiogenVumerity$1,319$358,74742 claims
AbbVieUbrelvy, Qulipta, Namzaric$3,193$243,246209 claims
PfizerNurtec Odt$783$152,649127 claims
Acadia Pharmaceuticals IncNuplazid$182$100,54018 claims
SK Life Science, Inc.Xcopri$621$98,77474 claims
Otsuka America Pharmaceutical, Inc.Rexulti$113$39,23222 claims
UCB, Inc.Vimpat, Briviact$1,439$36,91923 claims
Sunovion Pharmaceuticals Inc.Aptiom$648$26,27117 claims
Lilly USA, LLCCymbalta$231$5,15318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →